论文部分内容阅读
目的探讨多巴丝肼片联合盐酸司来吉兰治疗帕金森病(PD)患者的有效性和安全性。方法选取2014年5月至2015年5月梅州市中医医院收治的PD患者70例为研究对象,按随机数字表法分为观察组和对照组,每组35例。对照组患者采用多巴丝肼片治疗,观察组患者采用多巴丝肼片联合盐酸司来吉兰治疗,观察两组患者临床治疗效果。结果观察组患者治疗总有效率为80.0%,高于对照组的60.0%,差异有统计学意义(P<0.05);观察组患者的精神状态、运动功能、日常活动等帕金森统一评分量表评分均优于对照组,差异均有统计学意义(均P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用多巴丝肼片联合盐酸司来吉兰治疗PD疗效确切,可有效缓解患者的临床症状,减轻患者的不适,不良反应少,安全性高,可作为治疗PD的首选方法。
Objective To investigate the efficacy and safety of dobesilazine tablets combined with selegiline hydrochloride in the treatment of Parkinson’s disease (PD). Methods Seventy patients with PD who were admitted to Meizhou TCM Hospital from May 2014 to May 2015 were selected as study objects and divided into observation group and control group according to random number table method, with 35 cases in each group. Patients in the control group were treated with dopprous hydrazine tablets. The patients in the observation group were treated with dopprous hydrazine tablets and selegiline hydrochloride, and the clinical effects were observed in both groups. Results The total effective rate of observation group was 80.0%, which was higher than that of control group (60.0%), the difference was statistically significant (P <0.05). The Parkinson’s Unified Rating Scale such as mental state, motor function, daily activities, The score was better than the control group, the difference was statistically significant (all P <0.05); two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion The combination of dopas hydrazine tablets and selegiline Hydrochloride for the treatment of PD can effectively relieve the patients ’clinical symptoms, relieve the patients’ discomfort, reduce the adverse reaction, and have high safety. It can be used as the first choice for the treatment of PD.